HCV non-structural protein mutants and uses thereof

Details HCV non-structural protein mutants and uses thereof HCV non-structural protein mutants and uses thereof

2005-08-26

2009-02-17

Le, Emily M. (Department: 1648)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S005000, C530S350000

Reexamination Certificate

active

07491808

ABSTRACT:
Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.

REFERENCES:
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5843752 (1998-12-01), Dasmahapatra et al.
patent: 6153579 (2000-11-01), Kim et al.
patent: 6211338 (2001-04-01), Malcolm et al.
patent: 6333186 (2001-12-01), Wittekind et al.
patent: 6524589 (2003-02-01), Reichert et al.
patent: 6800456 (2004-10-01), Wittekind et al.
patent: 2002/0146685 (2002-10-01), Chien et al.
patent: 0 693 687 (1996-01-01), None
patent: WO 97/44469 (1997-11-01), None
patent: WO 00/01718 (2000-01-01), None
patent: WO 01/30812 (2001-05-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 2004/005473 (2004-01-01), None
Bartenschlager et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. Journal of Virology, Jul. 1993, vol. 67, No. 7, 3835-3844.
Bartenschlager et al., “Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions,” J. Virology 67:3835-3844, 1993.
Botarelli et al., “T-lymphocyte response to hepatitis C virus in different clinical courses of infection,” Gastroenterology 104:580-587, 1993.
Chen et al., “Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein,” Hepatology 28:219-224, 1998.
Choo et al., “Genetic organization and diversity of the hepatitis C virus,” Proc. Natl. Acad. Sci. USA 88:22451-5, 1991.
Cooper et al., “Analysis of a successful immune response against hepatitis C virus,” Immunity 10:439-449, 1999.
De Francesco et al., “The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase,” Antiviral Therapy 3(Supp. 3):99-109, 1998.
Diepolder et al., “Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection,” Lancet 346:1006-1007, 1995.
Diepolder et al., “Immunodominant CD4 T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection,” J. Virology 71:6011-6019, 1997.
Eckart et al., “The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor,” Biochemical and Biophysical Research Communications, vol. 192(2):399-406, 1993.
Ferrari et al., “T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections,” Hepatology 19:286-295, 1994.
Grakoui et al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites,” Jor. Virol. 67(5):2832-43, 1993.
Hoffman et al., “Mapping of immunodominant CD4 T lymphocyte epitiopes of hepatitis C virus antigens and their relevance durign the course of chronic infection,” Hepatology 21:632-638, 1995.
Iwata et al., “Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection,” Hepatology 22:1057-1064, 1995.
Koch et al., “Role of Charged Residues in the Catalytic Mechanism of Hepatitis C Virus NS3 Protease: Electrostatic Precollision Guidance and Transition-State Stabilization,” Biochem. 40:631-640, 2001.
Lin et al., “Immunoreactive HCV NS3/4a Protein Without NS3 Serine Protease Activity,” Transfusion 44(Supp):86A, 2004.
Minutello et al., “Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4 T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C,” J. Exp. Med. 178:17-25, 1993.
Missale et al., “Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response,” J. Clin. Invest. 98:706-714, 1996.
Schechter et al., “On the size of the active site in proteases,” Biochem. Biophys. Res. Comm. 27(2):157-62, 1967.
Tsai et al., “Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity,” Hepatology 25:449-458, 1997.
Tsai et al., “Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus,” Hepatology 21:908-912, 1995.
Dimasi et al., “Engineering, Characterization and Phage Display of Hepatitis C Virus NS3 Protease and NS4a Cofactor Peptide as a Single-Chain Protein,” Protein Engineering 11(12):1257-1265 (1998).
Howe et al., “A Novel Recombinant Single-Cain Hepatitis C Virus NS3-NS4a Protein With Improved Helicase Activity,” Protein Science 8:1332-1341 (1999).
Lin et al., “A Central Region in the Hepatitis C Virus NS4a Protein Allows Formation of an Active NS3-NS4a Serine Proteinase Complex in Vivo and in Vitro,” Journal of Virology 69(7):4373-4380 (1995).
Lin et al., “The Hepatitis C Virus NS3 Serine Proteinase and NS4a Cofactor: Establishment of a Cell-Free Trans-Processing Assay,” Proc. Natl. Acad. Sci. 92:7622-7626 (1995).
Pasquo et al., “Rational Design and Functional Expression of a Constitutively Active Single-Chain NS4a-NS3 Proteinase,” Research Paper, Folding & Design 3(6):433-441 (1998).
Taremi et al., “Construction, Expression, and Characterization of a Novel Fully Activated Recombinant Single-Chain Hepatitis C Virus Protease,” Protein Science 7:2143-2149 (1998).

Affiliated with

Also associated with

Rating

HCV non-structural protein mutants and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HCV non-structural protein mutants and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV non-structural protein mutants and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4112316